TrxR-IN-2
TrxR-IN-2 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-2 increases reactive oxidative species (ROS) levels and decreases mitochondrial transmembrane potential levels. TrxR-IN-2 triggers DNA damage via H2AX regulation, and induces autophagy via LC3, beclin-1, and p62 regulation. TrxR-IN-2 can be used for the research of drug-resistant hepatocellular carcinoma[1].
For research use only. We do not sell to patients.
- CAS No.: 2866261-50-7
- Formula: C22H22N4O4
- Molecular Weight:406.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Bel-7402 | IC50 |
0.8 μM
Compound: 11
|
Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human Bel-7402 cells incubated for 24 hrs by MTT assay
|
[PMID: 34806369] |
| Bel7402/5-FU | IC50 |
0.9 μM
Compound: 11
|
Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human BEL-7402/5-FU cells incubated for 24 hrs by MTT assay
|
[PMID: 34806369] |
| HepG2 | IC50 |
1.1 μM
Compound: 11
|
Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay
|
[PMID: 34806369] |
| HGC-27 | IC50 |
1.4 μM
Compound: 11
|
Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells incubated for 24 hrs by MTT assay
|
[PMID: 34806369] |
In Vitro
TrxR-IN-2 (Compound 11) (72 h) potently inhibits the proliferation of Bel7402, HepG2, HGC27, and Bel-7402/5-FU cells with IC50 values ranging from 0.8 μM to 1.4 μM[1].
TrxR-IN-2 (0.2 μM) potently inhibits TrxR activity in Bel-7402/5-FU cells with an IC50 of 0.2 μM[1].
TrxR-IN-2 (0.3-3.0 μM; 24 h) induces dose-dependent ROS accumulation in Bel-7402/5-FU cells[1].
TrxR-IN-2 (1-10 μM) significantly reduces mitochondrial transmembrane potential in Bel-7402/5-FU cells[1].
TrxR-IN-2 (1.0-3.0 μM; 72 h) triggers DNA damage in Bel-7402/5-FU cells by up-regulating the expression of H2AX.S139ph, p-p53, and p53[1].
TrxR-IN-2 (1.0-3.0 μM; 24 h) induces dose-dependent autophagosome formation in Bel-7402/5-FU cells[1].
TrxR-IN-2 (0.3-3.0 μM; 72 h) triggers autophagy in Bel-7402/5-FU cells by dose-dependently increasing the LC3-II/LC3-I ratio and beclin-1 expression, and decreasing p62 expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Bel-7402/5-FU drug-resistant human liver carcinoma cells
-
Concentration:1.0 μM; 3.0 μM
-
Incubation Time:72 h
-
Result:Increased the expression of DNA damage biomarker H2AX.S139ph, phosphorylated p53 (p-p53), and total p53 in a dose-dependent manner.
-
Cell Line:Bel-7402/5-FU drug-resistant human liver carcinoma cells
-
Concentration:1.0 μM; 3.0 μM
-
Incubation Time:24 h
-
Result:Induced autophagosome formation in a dose-dependent manner; at 3.0 μM, triggered autophagy more pronouncedly than piperlongumine at the same concentration.
-
Cell Line:Bel-7402/5-FU drug-resistant human liver carcinoma cells
-
Concentration:0.3 μM; 1.0 μM; 3.0 μM
-
Incubation Time:72 h
-
Result:Up-regulated the conversion of LC3-I to LC3-II (increasing the LC3-II/LC3-I ratio in a dose-dependent manner) and the expression of beclin-1, while down-regulating the expression of p62.
Was more potent than piperlongumine in modulating these protein levels.
In Vivo
TrxR-IN-2 (2-5 mg/kg; i.p.; 21 days) exhibits potent in vivo antitumor activity in Bel-7402/5-FU xenograft nude mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice (female)[1]
-
Dosage:60.0 mg/kg; 90.0 mg/kg; 135.0 mg/kg; 202.5 mg/kg; 303.8 mg/kg
-
Administration:i.p.; single dose
-
Result:Achieved 100% survival of mice 14 days post-administration at 60.0 mg/kg.
Achieved 90% survival of mice 14 days post-administration at 90.0 mg/kg.
Achieved 60% survival of mice 14 days post-administration at 135.0 mg/kg.
Achieved 30% survival of mice 14 days post-administration at 202.5 mg/kg.
Achieved 10% survival of mice 14 days post-administration at 303.8 mg/kg.
Calculated a median lethal dose (LD50) of 178 mg/kg.
-
Animal Model:Nude mice (Bel-7402/5-FU xenograft tumor model)[1]
-
Dosage:2 mg/kg; 5 mg/kg
-
Administration:i.p.; 21 days
-
Result:Significantly suppressed tumor growth compared to the control group at 2 mg/kg, reducing mean tumor weight to ~0.7 g.
Suppressed tumor growth by 76% compared to the control group at 5 mg/kg, reducing mean tumor weight to ~0.45 g.
Showed greater tumor growth inhibition than the 5 mg/kg dose of piperlongumine at 5 mg/kg.
Chemical Information
-
CAS No. 2866261-50-7
-
Molecular Weight 406.43
-
Formula C22H22N4O4
-
SMILES
O=C1C=CCCN1C(/C=C/C2=NC(C)=C(/C=C/C(N3CCC=CC3=O)=O)N=C2C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)